Introduction: Tobacco use typically begins during adolescence. There is a lack of comprehensive evidence on the use of different tobacco products among adolescents in Africa. Aims and Methods: We used the most recent Global Youth Tobacco Surveys data from 53 African countries, covering 2003-2020, to estimate the overall and gender-specific prevalence of each type of tobacco product by country, Africa region, World Bank income group, and age group. We further used independent logit regression models to assess the determinants of the use of different types of tobacco products. The datasets covered 204,537 primary/secondary school-going adolescents aged 11-17 years. Pooled prevalence estimates were computed using the individual-level data. Results: The overall prevalence of any tobacco use among African adolescents was 14.3% [95% CI: 13.5, 15.3]. Specifically, the prevalence for cigarette smoking was 6.4% [95% CI: 5.9, 7.0], for other smoked tobacco was 6.7% [95% CI: 6.0, 7.4], for smokeless tobacco use was 6.4% [95% CI: 5.9, 6.9], and for shisha smoking was 5.2% [95% CI: 4.4, 6.1]. The prevalence of dual use of smoked and smokeless tobacco was 3.0% [95% CI: 2.8, 3.2], and that of shisha and cigarettes was 1.5% [95% CI: 1.2, 2.0]. The prevalence of any tobacco use was higher among boys (17.4%) than girls (10.6%). Exposure to anti-tobacco smoking messages, exposure to smoking at home and school, the age restriction to tobacco purchases, and peer pressure were positively associated with the tobacco use, irrespective of product type. Being a female was a protective factor of tobacco use for almost all products. Country-level factors such as predominant religion, African region, and World Bank income group were significant factors only for cigarettes and shisha smoking. Conclusions: The prevalence of tobacco use among African adolescents aged 11-17 years is high, but similar across different tobacco products. Peer pressure and school environment significantly influence adolescents' decisions to participate in tobacco use. Policymakers could prioritize implementing large pictorial health warnings about tobacco dangers covering the entire packaging of different products.

The authors have declared no competing interest.

This work was supported by the Bill & Melinda Gates Foundation (INV-048743).

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes